Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

As Professor Kim mentioned, chronic kidney disease (CKD) develops in up to 45% of patients following liver transplantation (LT), significantly impacting patient survival. [2][3]3][4] Similarly, in our study, approximately 36% (n=341) of the 952 included patients developed CKD during a median follow-up of 97.3 months. 5Given the impact of CKD on increased mortality in LT patients, identifying risk factors for CKD and end-stage renal disease (ESRD), as assessed in our study, remains a critical issue in LT management.As Professor Kim commented, multiple factors contribute to the development of CKD after LT in a complex manner.In this context, identifying the optimal trough level of tacrolimus-a cornerstone immunosuppressant for LT patientsto reduce CKD risk, alongside other potential risk factors,